methyl 4-<2-(2,4-diaminothieno<2,3-d>pyrimidin-5-yl)ethyl>benzoate | 136784-85-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-<2-(2,4-diaminothieno<2,3-d>pyrimidin-5-yl)ethyl>benzoate
• 英文别名: methyl 4-[2-(2,4-diaminothieno[2,3-d]pyrimidin-5-yl)ethyl]benzoate；Methyl 4-[2-(2,4-diamino-thieno[2,3-d]pyrimidine-5-yl)ethyl]benzoate
• CAS: 136784-85-5
• 化学式: C₁₆H₁₆N₄O₂S
• 分子量: 328.395
• InChiKey: SWZWPRVLOQTZET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  132
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 4-<2-(2,4-diaminothieno<2,3-d>pyrimidin-5-yl)ethyl>benzoate 在 N-甲基吗啉 、 sodium hydroxide 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.0h， 生成 dimethyl N-<4-<2-(2,4-diaminothieno<2,3-d>pyrimidin-5-yl)ethyl>benzoyl>-L-glutamate
  参考文献：
  名称：

  Synthesis of Thieno[2,3-d]pyrimidine Analogues of the Potent Antitumor Agent N-{4-[2-(2-Amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic Acid (LY231514)

  摘要：

  DOI：

  10.3987/com-95-7269
• 作为产物：
  描述：

  4-<2,4-diaminopyrimidin-6-yl>thio-4-(4-carbomethoxyphenyl)-2-butanone 在 对甲苯磺酸 作用下， 以 乙二醇 为溶剂， 以55%的产率得到methyl 4-<2-(2,4-diaminothieno<2,3-d>pyrimidin-5-yl)ethyl>benzoate
  参考文献：
  名称：

  Synthesis of Thieno[2,3-d]pyrimidine Analogues of the Potent Antitumor Agent N-{4-[2-(2-Amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic Acid (LY231514)

  摘要：

  DOI：

  10.3987/com-95-7269

文献信息

• Condensed heterocyclic glutamic acid derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0438261A3

  公开（公告）日：1992-02-26

  Novel compounds of the formula: wherein the ring A is a 5-membered ring, provided that, in the case where the ring A is a pyrrole or pyrroline ring, (i) the N atom in the ring has no active proton or (ii) the ring bonds to Z at the -position of the ring;    B is a divalent cyclic or chain group which may be substituted; one of Q¹ and Q² is N, with the other being N or CH; Y is a hydrogen or halogen atom or a group which bonds to the bonding line with a carbon, nitrogen, oxygen or sulfur atom; X is an amino, hydroxyl or mercapto group;    Z is a straight-chain divalent group having a number of atoms of 2 to 5 composed of carbon atoms which each may be substituted, or of carbon atoms which each may be substituted and one hetero atom which may be substituted;    -COOR¹ and -COOR² each is the same as or different from the other and represents a carboxyl group which may be esterified or its salts are produced by reacting compounds of the formula, wherein A, B, Q¹, Q², X, Y, and Z are the same as defined above, with compounds of the formula, wherein -COOR¹ and -COOR² are the same as defined above.The compounds are useful as an antitumor agent.

  根据以下公式的新化合物：其中环A是一个5元环，前提是，在环A为吡咯或吡咯烯环的情况下，(i)环中的N原子没有活性质子或(ii)环与Z在环的位置结合；B是可能被取代的二价环或链基团；Q¹和Q²中的一个是N，另一个是N或CH；Y是氢原子或卤素原子，或与碳、氮、氧或硫原子形成键合线的基团；X是氨基、羟基或巯基基团；Z是直链二价基团，由2到5个碳原子组成，每个碳原子可能被取代，或由每个可能被取代的碳原子和一个可能被取代的杂原子组成；-COOR¹和-COOR²分别与另一个相同或不同，并表示可以酯化的羧基或其盐，通过将具有上述定义的A、B、Q¹、Q²、X、Y和Z的化合物与具有上述定义的-COOR¹和-COOR²的化合物反应而产生。这些化合物可用作抗肿瘤剂。
• Condensed pyrimidine derivatives, their production and use as antitumor agents
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0530537A1

  公开（公告）日：1993-03-10

  A condensed pyrimidine derivative of the formula (I): wherein the ring A stands for an optionally substituted 5-membered ring; B stands for an optionally substituted divalent 5- or 6-membered homo- or hetero-cyclic group; X stands for, among others, amino group; Y stands for, among others, hydrogen atom, halogen atom or amino group; Z stands for a divalent aliphatic group having five or less atoms forming straight chain, optionally having nitrogen, whose chain portion may optionally have a hetero-atom; W stands for, among others, -NH-CO-or -CO-NH-; R¹ stands for an optionally substituted cyclic or chain-like group ; COOR² stands for an optionally esterified carboxyl group; and p denotes an integer of 1 to 4, provided that when -W-R¹ denotes a moiety represented by the formula: wherein COOR¹⁶ and COOR¹⁷ are, independently, an optionally esterified carboxyl group and n denotes an integer of 1 to 5, p denotes 1, 3 or 4, or a salt thereof, exhibiting highly specific toxicities to various tumor cells and excellent therapeutic effects on methotrexate-resistant tumor cells as well.

  式 (I) 的缩合嘧啶衍生物： 其中，环 A 代表任选取代的 5 元环；B 代表任选取代的二价 5 元或 6 元同环或杂环基团；X 代表氨基；Y 代表氢原子、卤素原子或氨基；Z 代表二价脂肪族基团，该基团具有 5 个或更少原子，形成直链，可任选具有氮，其链部分可任选具有杂原子；W 表示-NH-CO-或-CO-NH-；R¹ 表示任选取代的环状或链状基团；COOR² 表示任选酯化的羧基；p 表示 1 至 4 的整数，条件是当 -W-R¹ 表示由式表示的分子时： 其中 COOR¹⁶和 COOR¹⁷分别为任选酯化的羧基，n 表示 1 至 5 的整数，p 表示 1、3 或 4，或其盐，对各种肿瘤细胞具有高度特异性毒性，对甲氨蝶呤耐药的肿瘤细胞也有极好的治疗效果。
• US5403843A
  申请人：——

  公开号：US5403843A

  公开（公告）日：1995-04-04
• Synthesis of Thieno[2,3-d]pyrimidine Analogues of the Potent Antitumor Agent N-{4-[2-(2-Amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic Acid (LY231514)
  作者：Edward C. Taylor、Hemantkumar H. Patel、Gowravaram Sabitha、Rajendra Chaudhari

  DOI：10.3987/com-95-7269

  日期：——